Prof. Geoffrey Dusheiko Royal Free Hospital, London, UK

1 Talk
Biography

Geoffrey Dusheiko, MD, MB, BCh, is Emeritus Professor of Medicine at the Royal Free Hospital and University College London School of Medicine and Consultant Hepatologist at Kings College Hospital London, in London, UK. After earning his MBBS degree from the University of Witwatersrand in Johannesburg, South Africa, Professor Dusheiko completed... read morehis internship at the Chris Hani Baragwanath Hospital in Johannesburg and his residency at Johannesburg Hospital. His fellowships were conducted at the Johannesburg Hospital Liver Unit and the National Institutes of Health, Maryland, and the University of Minnesota, USA. Professor Dusheiko’s research interests include the management and treatment of HCV and HBV and small hepatocellular carcinoma; he has a special interest in research on viral hepatitis, especially viral genotyping, applied molecular virology, the natural history of chronic viral hepatitis and antiviral therapies. A member of several organisations, including EASL, AASLD and IASL, Professor Dusheiko is also a Fellow of the Royal College of Physicians, the Royal College of Physicians of South Africa, and the Royal College of Physicians of Edinburgh. He previously served as Educational Councillor on the Governing Board of EASL for 4 years and was the recipient of the EASL Recognition Award in 2014. An advisor for the UK National Institute of Health and Care Excellence, Professor Dusheiko is an author of the World Health Organization’s HBV guidelines and he is the Director of the Skipton Fund, a UK ex gratia payment scheme for patients infected with HCV through contaminated blood products. A member of the editorial board of the Journal of Viral Eradication, he is Co-editor of Alimentary Pharmacology and Therapeutics, and has previously served on editorial boards for the Journal of Viral Hepatitis, Hepatology, Best Practice & Research Clinical Gastroenterology, and Gut among others. Professor Dusheiko has authored or co-authored more than 360 articles in international peer-reviewed journals or books.